Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chloroquine phosphate plus standard therapy versus placebo plus standard therapy in mild/common COVID-19
ChiCTR2000029837Phase 4Not yet recruiting
- Sponsor
- Jingzhou Central Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Chloroquine phosphate group with Placebo group (2 arms). Primary endpoint: Time of conversion to negative for novel coronavirus nucleic acid. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
chloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029837.